التفاصيل البيبلوغرافية
| العنوان: |
The Association of Intravitreal Anti-VEGF Injections With Kidney Function in Diabetic Retinopathy |
| المؤلفون: |
Casey C. Bunge, MD, Prarthana J. Dalal, MD, PhD, Elizabeth Gray, MS, Kasen Culler, MD, Julia J. Brown, MD, Susan E. Quaggin, MD, Anand Srivastava, MD, MPH, Manjot K. Gill, MD |
| المصدر: |
Ophthalmology Science, Vol 3, Iss 4, Pp 100326- (2023) |
| بيانات النشر: |
Elsevier, 2023. |
| سنة النشر: |
2023 |
| المجموعة: |
LCC:Ophthalmology |
| مصطلحات موضوعية: |
diabetic retinopathy, diabetic macular edema, intravitreal injections, anti-vascular endothelial growth factor, anti-VEGF, Ophthalmology, RE1-994 |
| الوصف: |
Purpose: To examine whether patients with diabetic retinopathy receiving intravitreal anti-VEGF injections are at increased risk of kidney function decline. Design: Retrospective cohort study. Participants: Included 187 patients who received intravitreal anti-VEGF injections for proliferative diabetic retinopathy (PDR) and/or diabetic macular edema (DME), and 929 controls with non-PDR who did not receive injections, at a large tertiary care center in Chicago, Illinois. Methods: We queried our institutional enterprise data warehouse to identify patients with diabetic retinopathy, determined whether they received intravitreal anti-VEGF injections, and followed kidney function for all patients over time. Main Outcome Measures: We assessed time to sustained 40% decline in estimated glomerular filtration rate (eGFR) from baseline in patients receiving intravitreal anti-VEGF injections and compared it with controls using Kaplan-Meier and multivariable adjusted Cox proportional hazards regression models. Results: This study included 1116 patients (565 female [50.6%]; mean [standard deviation {SD}] age, 57.3 [13.6] years; mean [SD] eGFR, 65.3 [32.1] ml/min/1.73 m2). Of these, 187 patients received ≥ 1 intravitreal anti-VEGF injection (mean [SD], 11.4 [13.1] injections) for PDR and/or DME, and 929 controls with non-PDR received no injections. Intravitreal anti-VEGF injection use was not associated with an increased risk of kidney function decline (hazard ratio [HR], 1.44; 95% confidence interval [CI], 0.97–2.15). Subgroup analyses revealed that use of intravitreal anti-VEGF injections was associated with increased risk of kidney function decline in male patients (HR, 1.87; 95% CI, 1.11–3.14) but not female patients (HR, 0.97; 95% CI, 0.50–1.89). Intravitreal anti-VEGF injection use was also associated with an increased risk of kidney function decline in patients with baseline eGFR > 30 ml/min/1.73 m2 (HR, 1.86; 95% CI, 1.15–3.01), but not in individuals with baseline eGFR ≤ 30 ml/min/1.73 m2 (HR, 0.97; 95% CI, 0.45–2.10). Among patients who received injections, receiving ≥ 12 injections was not associated with risk of kidney function decline (HR, 1.13; 95% CI, 0.52–2.49). Conclusions: Intravitreal anti-VEGF injections for patients with diabetic retinopathy are overall well-tolerated with respect to kidney function, but the use of intravitreal anti-VEGF injections was associated with an increased risk of kidney function decline in certain subgroups of patients. Financial Disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article. |
| نوع الوثيقة: |
article |
| وصف الملف: |
electronic resource |
| اللغة: |
English |
| تدمد: |
2666-9145 |
| Relation: |
http://www.sciencedirect.com/science/article/pii/S2666914523000581; https://doaj.org/toc/2666-9145 |
| DOI: |
10.1016/j.xops.2023.100326 |
| URL الوصول: |
https://doaj.org/article/3a394ef76e17499592334e84e505ae21 |
| رقم الانضمام: |
edsdoj.3a394ef76e17499592334e84e505ae21 |
| قاعدة البيانات: |
Directory of Open Access Journals |
Full Text Finder